Yet another failed drug trial has prompted soul-searching about the “amyloid hypothesis.” Last week, the pharmaceutical company Merck pulled the plug on a closely watched Alzheimer’s drug trial. The drug verubecestat, an outside committee concluded, had “virtually no chance” of benefit for patients with the disease. The failure of one drug is of course disappointing, but verubecestat is only the l